AMGN
AmgenNASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-05-08
As of May 8, 2026, AMGN has a composite score of 11.4, categorized with a signal label of "mild favorable." This score is influenced by a medium confidence level of 74.4 and reflects various factors, including a macro score of 31.5 and a momentum score of -17.0. The analysis is provisional, indicating that the data may be subject to change.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share1.00
- Slope (norm)-0.60
- Bonus0.00
Why this rank
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $5.79 → $5.62 (-2.9% / 30d). 5 raised, 15 cut, 26 covering analysts.
0 upgrades, 0 downgrades / 30d, 5 maintained. 37% of analysts rate Buy.
5 PT revisions / 30d. Avg target -0.1% above current price.
0 positive, 0 negative / 30d.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
3 material events in the last 24 months — top 3 listed below.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Integrate science, technology, and datatalentwatch50% progress
4/22: “Amgen announced the retirement of its CTO to further integrate science, technology, and data.”
Why this status
Newly stated in 2026-Q1. Amgen announced the retirement of its CTO to facilitate the integration of science, technology, and data. This strategic move aims to enhance the alignment of commercial, medical, and policy teams. The financials do not yet reflect specific outcomes from this integration effort.
- 2.Manage capital through debt issuancecapital allocationmixed37% progress
2/19: “Amgen issued $4 billion in senior notes to manage its capital structure.”
Why this status
Newly stated in 2026-Q1. Amgen issued $4 billion in senior notes to manage its capital structure. This capital allocation strategy is aimed at optimizing the company's financial flexibility. The financials do not yet show the impact of this debt issuance on operating metrics.
- 3.Deliver long-term growth through innovationgrowthmixed65% progress
4/30: “CEO: 'We're confident in our ability to deliver attractive long-term growth.'”
Why this status
Newly stated in 2026-Q1. Amgen's CEO expressed confidence in delivering long-term growth through innovation and pipeline expansion. The financials show a 6% revenue increase to $8.6 billion in 2026-Q1, indicating some progress, but the trajectory of innovation-driven growth remains to be fully demonstrated.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 25%; 252d 28%.
Drawdown — Max 1y −17%. Bad day move −3%.
Beta to sector ETF (XLV) — 1.24 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 54/100, drawdown 67/100, beta 76/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Integrate science, technology, and data
TalentNew since 2026-05-04Facilitate integration of science, technology, and data to enhance alignment of commercial, medical, and policy teams.
WatchNewly stated in 2026-Q1. Amgen announced the retirement of its CTO to facilitate the integration of science, technology, and data. This strategic move aims to enhance the alignment of commercial, medical, and policy teams. The financials do not yet reflect specific outcomes from this integration effort.
50%CEO/CFO:“Amgen announced the retirement of its CTO to further integrate science, technology, and data.”Multiple sourcesSource dated 2026-04-22Stated 1 of last 8 quartersFirst seen 2026-05-04Show history (1)
- 2026-Q1Multiple sources
“Amgen announced the retirement of its CTO to further integrate science, technology, and data.”
- #2
Manage capital through debt issuance
Capital allocationNew since 2026-05-04Amgen is managing its capital structure through the issuance of senior notes.
MixedNewly stated in 2026-Q1. Amgen issued $4 billion in senior notes to manage its capital structure. This capital allocation strategy is aimed at optimizing the company's financial flexibility. The financials do not yet show the impact of this debt issuance on operating metrics.
Amgen issued $4 billion in senior notes37%CEO/CFO:“Amgen issued $4 billion in senior notes to manage its capital structure.”Multiple sourcesSource dated 2026-02-19Stated 1 of last 8 quartersFirst seen 2026-05-04Show history (1)
- 2026-Q1Multiple sources
“Amgen issued $4 billion in senior notes to manage its capital structure.”
- #3
Deliver long-term growth through innovation
GrowthAmgen aims to deliver long-term growth by advancing innovative therapies and expanding its pipeline.
MixedNewly stated in 2026-Q1. Amgen's CEO expressed confidence in delivering long-term growth through innovation and pipeline expansion. The financials show a 6% revenue increase to $8.6 billion in 2026-Q1, indicating some progress, but the trajectory of innovation-driven growth remains to be fully demonstrated.
65%CEO/CFO:“CEO: 'We're confident in our ability to deliver attractive long-term growth.'”Earnings callSource dated 2026-04-30Stated 1 of last 8 quartersFirst seen 2026-04-30Show history (1)
- 2026-Q1Earnings call
“CEO: 'We're confident in our ability to deliver attractive long-term growth.'”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Roughly priced in line with peers.
Cheaper than its own typical valuation.
P/E over the last 5 years
71 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
AMGN Amgen | +11 | fair | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is raised (currently NEW as of 2023-10-06)+4.0 pts
- If next-quarter guidance is cut (currently NEW as of 2023-10-06)-8.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-04-2217d agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 22, 2026, Amgen Inc. (the “Company”) publicly announced that David M. Reese is retiring from the role of the Company’s Executive Vice President and Chief Technology Officer. To facilitate the further integration of our science, technology and data and build on the strong alignment of our commercial, medical and policy teams, the responsibi…
executive changeneutralscore 54 - 2026-04-309d agoItem 2.02
Results of Operations and Financial Condition. First Quarter 2026 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On April 30, 2026 , the Company issued a press release announcing its unaudited results of operations for the three months ended March 31, 2026, and its unaudited financial position as of March 31, 2026. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain non-U.S. Generally Accepted Acco…
earnings preannouncementneutralscore 54 - 2026-02-192mo agoItem 1.01
Entry into a Material Definitive Agreement. On February 17, 2026, Amgen Inc. (the “Company”) issued and sold $1,000,000,000 aggregate principal amount of the Company’s 4.200% Senior Notes due 2031 (the “2031 Notes”), $1,750,000,000 aggregate principal amount of the Company’s 4.850% Senior Notes due 2036 (the “2036 Notes”), $500,000,000 aggregate principal amount of the Company’s 5.500% Senior Notes due 2046 (the “2046 Notes”) and $750,000,000 aggregate principal amount of the Company’s 5.650%…
capital allocationneutralscore 11 - 2026-02-033mo agoItem 2.02
Results of Operations and Financial Condition. Fourth Quarter and Full Year 2025 Earnings Press Release and Reconciliation of Non-GAAP Financial Measures On February 3, 2026 , the Company issued a press release announcing its unaudited results of operations for the three months and year ended December 31, 2025, and its unaudited financial position as of December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 hereto. In its press release the Company included certain…
earnings preannouncementpositivescore 8 - 2026-01-303mo agoItem 1.02
Termination of a Material Definitive Agreement. On January 30, 2026, Amgen Inc. (the “ Company ”) entered into a Termination Agreement (the “ Termination Agreement ”) with Kyowa Kirin Co., Ltd. (“ Kyowa Kirin ”), pursuant to which the Company and Kyowa Kirin agreed to terminate the License and Collaboration Agreement, dated June 1, 2021 (the “ License and Collaboration Agreement ”). The termination of the License and Collaboration Agreement will become effective upon receipt of regulatory app…
mna activitynegativescore 5
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.